BioMarin Pharmaceutical (BMRN) Competitors

Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Which has higher earnings and valuation, BIIB or BMRN?

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.97	$1.63B	$10.13	12.85
BioMarin Pharmaceutical	$2.85B	3.86	$426.86M	$2.69	21.34

Is BIIB or BMRN more profitable?

BioMarin Pharmaceutical has a net margin of 17.76% compared to Biogen's net margin of 15.07%. Biogen's return on equity of 14.03% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.07%	14.03%	8.32%
BioMarin Pharmaceutical	17.76%	11.34%	8.95%

Which has more volatility & risk, BIIB or BMRN?

Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

Does the media prefer BIIB or BMRN?

In the previous week, Biogen and Biogen both had 9 articles in the media. BioMarin Pharmaceutical's average media sentiment score of 0.87 beat Biogen's score of 0.75 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate BIIB or BMRN?

Biogen presently has a consensus price target of $188.48, indicating a potential upside of 44.84%. BioMarin Pharmaceutical has a consensus price target of $93.61, indicating a potential upside of 63.05%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
BioMarin Pharmaceutical	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do insiders and institutionals have more ownership in BIIB or BMRN?

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Biogen on 11 of the 15 factors compared between the two stocks.